Pelthos Therapeutics (PTHS) Non Operating Income (2023 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Non Operating Income of -$16.6 million for Q4 2025, down 16157.84% year-over-year from N/an in Q4 2024, and down 1136.61% quarter-over-quarter from -$1.3 million in Q3 2025.
Pelthos Therapeutics (PTHS) Non Operating Income (2023 - 2026) Analysis & Trends
Pelthos Therapeutics' Non Operating Income history runs 3 years deep, the most recent figure standing at -$16.6 million for Q4 2025.
- In Q4 2025, Non Operating Income fell 16157.84% year-over-year to -$16.6 million; the TTM figure through Dec 2025 stood at -$18.3 million (down 4660.89% YoY), while the FY2025 annual figure was -$18.3 million, down 4659.38% from the prior year.
- Non Operating Income for Q4 2025 stood at -$16.6 million, down from -$1.3 million in the prior quarter.
- The five-year high for Non Operating Income was $354000.0 in Q3 2024, with the low at -$16.6 million in Q4 2025.
- The 3-year median for Non Operating Income is -$146986.0 (2023), against an average of -$1.6 million.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income jumped 372.3% in 2024, then tumbled 16157.84% in 2025.
- Pelthos Therapeutics' Non Operating Income stood at -$160338.0 in 2023, then soared by 36.38% to -$102000.0 in 2024, then sank by 16157.84% to -$16.6 million in 2025.
- Business Quant data shows PTHS's Non Operating Income at -$16.6 million in Q4 2025, -$1.3 million in Q3 2025, and -$218516.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | -18.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.08 Mn |
| Dec 31, 2025 | -16.58 Mn |
| Sep 30, 2025 | -1.34 Mn |
| Jun 30, 2025 | -218,516.00 |
| Mar 31, 2025 | -133,634.00 |
| Dec 31, 2024 | -102,000.00 |
| Sep 30, 2024 | 354,000.00 |
| Jun 30, 2024 | -7,533.00 |
| Mar 31, 2024 | -628,348.00 |
| Dec 31, 2023 | -160,338.00 |
| Sep 30, 2023 | -130,006.00 |
| Jun 30, 2023 | -176,187.00 |
| Mar 31, 2023 | -51,978.00 |